113 related articles for article (PubMed ID: 35710743)
1. Disease monitoring using lung function trajectory in lymphangioleiomyomatosis: assessment in two national cohorts.
Johnson J; Stewart I; Johnson SR
Thorax; 2023 Jan; 78(1):61-68. PubMed ID: 35710743
[TBL] [Abstract][Full Text] [Related]
2. Rates of change in FEV
Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
[TBL] [Abstract][Full Text] [Related]
3. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.
Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
[TBL] [Abstract][Full Text] [Related]
4. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts.
Taveira-DaSilva AM; Johnson SR; Julien-Williams P; Johnson J; Stylianou M; Moss J
Thorax; 2020 Oct; 75(10):904-907. PubMed ID: 32788260
[TBL] [Abstract][Full Text] [Related]
6. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.
Taveira-DaSilva AM; Stylianou MP; Hedin CJ; Hathaway O; Moss J
Chest; 2004 Dec; 126(6):1867-74. PubMed ID: 15596686
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
Yoon HY; Hwang JJ; Kim DS; Song JW
Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
[TBL] [Abstract][Full Text] [Related]
8. Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis.
Matthew BP; Hasani AM; Chen YC; Pirooznia M; Stylianou M; Rollison SF; Machado TR; Quade NM; Jones AM; Julien-Williams P; Taveira-DaSilva A; Chen MY; Moss J; Wen H
Chest; 2021 Jul; 160(1):199-208. PubMed ID: 33549601
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
[TBL] [Abstract][Full Text] [Related]
10. [Study on changes of pulmonary function in patients with pneumoconiosis in three years].
Li X; Dai WR; Liu WF; Yang ZX; Xie L; Wu ZY
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2020 Dec; 38(12):891-894. PubMed ID: 33406545
[No Abstract] [Full Text] [Related]
11. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
12. Carbon monoxide lung diffusion capacity improves risk stratification in patients without airflow limitation: evidence for systematic measurement before lung resection.
Brunelli A; Refai MA; Salati M; Sabbatini A; Morgan-Hughes NJ; Rocco G
Eur J Cardiothorac Surg; 2006 Apr; 29(4):567-70. PubMed ID: 16481190
[TBL] [Abstract][Full Text] [Related]
13. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database.
Hayashida M; Yasuo M; Hanaoka M; Seyama K; Inoue Y; Tatsumi K; Mishima M;
Respir Investig; 2016 May; 54(3):193-200. PubMed ID: 27108015
[TBL] [Abstract][Full Text] [Related]
14. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
15. Computer grading of lung disease severity in patients with lymphangioleiomyomatosis referred for transplantation.
Taveira-DaSilva AM; Gopalakrishnan V; Yao J; Chen MY; Julien-Williams P; Jones AM; Pacheco-Rodriguez G; Moss J
BMC Pulm Med; 2022 Sep; 22(1):362. PubMed ID: 36153516
[TBL] [Abstract][Full Text] [Related]
16. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study.
Bee J; Fuller S; Miller S; Johnson SR
Thorax; 2018 Apr; 73(4):369-375. PubMed ID: 28993539
[TBL] [Abstract][Full Text] [Related]
17. Influence of reduced diffusing capacity and FEV
Risom EC; Buggeskov KB; Petersen RH; Mortensen J; Ravn HB
Acta Anaesthesiol Scand; 2021 Oct; 65(9):1221-1228. PubMed ID: 34089538
[TBL] [Abstract][Full Text] [Related]
18. Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.
Courtwright AM; Baldi BG; Kidambi P; Cui Y; Lamattina AM; Villalba JA; Bagwe S; Goldberg HJ; Rosas IO; Henske EP; Carvalho CRR; El-Chemaly S
Sarcoidosis Vasc Diffuse Lung Dis; 2018; 35(3):206-212. PubMed ID: 32476904
[No Abstract] [Full Text] [Related]
19. Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Chest; 2018 Jan; 153(1):124-132. PubMed ID: 28533049
[TBL] [Abstract][Full Text] [Related]
20. Natural history of lung function over one year in patients with Parkinson's disease.
Kaminsky DA; Grosset DG; Kegler-Ebo DM; Cangiamilla S; Klingler M; Zhao P; Oh C
Respir Med; 2021 Jun; 182():106396. PubMed ID: 33866196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
